Clinical Trial Update: Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lenalidomide (Revlimid) as second-line therapy for chronic graft-versus-host disease was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Graft-versus-Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-12-11